51
|
Siddiqui I, Erreni M, Kamal MA, Porta C, Marchesi F, Pesce S, Pasqualini F, Schiarea S, Chiabrando C, Mantovani A, Allavena P. Differential role of Interleukin-1 and Interleukin-6 in K-Ras-driven pancreatic carcinoma undergoing mesenchymal transition. Oncoimmunology 2017; 7:e1388485. [PMID: 29308316 DOI: 10.1080/2162402x.2017.1388485] [Citation(s) in RCA: 22] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/29/2017] [Revised: 09/29/2017] [Accepted: 09/30/2017] [Indexed: 02/07/2023] Open
Abstract
K-Ras mutations are a hallmark of human pancreatic adenocarcinoma (PDAC) and epithelial-mesenchymal-transition (EMT) is a driver of progression. Oncogenic K-Ras causes the constitutive activation of NF-kB and the switch-on of an inflammatory program, which further fuels NF-kB and STAT3 activation. In this study we investigated how inflammatory pathways triggered by oncogenic K-Ras are regulated in human pancreatic cancer cells with distict epithelial or mesenchymal phenotype. Our results demonstrate that in cells with epithelial features, K-Ras driven inflammation is under the control of IL-1, while in cells undergoing EMT, is IL-1 independent. In pancreatic tumor cells with EMT phenotype, treatment with IL-1R antagonist (Anakinra) did not inhibit inflammatory cytokine production and tumor growth in mice. In these cells IL-6 is actively transcribed by the EMT transcription factor TWIST. Targeting of mesenchymal pancreatic tumors in vivo with anti-IL-6RmAb (RoActemra) successfully decreased tumor growth in immunodeficient mice, inhibited the inflammatory stroma and NF-kB-p65 and STAT3 phosphorylation in cancer cells. The results confirm that IL-1 is an important driver of inflammation in epithelial pancreatic tumors; however, tumor cells undergoing EMT will likely escape IL-1R inhibition, as IL-6 is continuously transcribed by TWIST. These findings have implications for the rational targeting of inflammatory pathways in human pancreatic cancer.
Collapse
Affiliation(s)
- Imran Siddiqui
- Department of Immunology, IRCCS Clinical and Research Institute Humanitas, Rozzano (Milano), Italy
| | - Marco Erreni
- Department of Immunology, IRCCS Clinical and Research Institute Humanitas, Rozzano (Milano), Italy
| | - Mohammad Azhar Kamal
- Department of Immunology, IRCCS Clinical and Research Institute Humanitas, Rozzano (Milano), Italy
| | - Chiara Porta
- Department of Pharmaceutical Sciences, Università Piemonte Orientale, Novara, Italy
| | - Federica Marchesi
- Department of Immunology, IRCCS Clinical and Research Institute Humanitas, Rozzano (Milano), Italy.,Department of Medical Biotechnology and Translational Medicine, University of Milan, Italy
| | - Samantha Pesce
- Department of Immunology, IRCCS Clinical and Research Institute Humanitas, Rozzano (Milano), Italy
| | - Fabio Pasqualini
- Department of Immunology, IRCCS Clinical and Research Institute Humanitas, Rozzano (Milano), Italy
| | - Silvia Schiarea
- Department of Environmental Health Sciences, IRCCS - Istituto di Ricerche Farmacologiche "Mario Negri", Milano, Italy
| | - Chiara Chiabrando
- Department of Environmental Health Sciences, IRCCS - Istituto di Ricerche Farmacologiche "Mario Negri", Milano, Italy
| | - Alberto Mantovani
- Department of Immunology, IRCCS Clinical and Research Institute Humanitas, Rozzano (Milano), Italy.,Humanitas University, Rozzano (Milano), Italy
| | - Paola Allavena
- Department of Immunology, IRCCS Clinical and Research Institute Humanitas, Rozzano (Milano), Italy.,Humanitas University, Rozzano (Milano), Italy
| |
Collapse
|